177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas By Ogkologos - September 2, 2025 161 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the Phase II study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Scientists Link a Single Type of Bacteria to Colorectal Cancer April 19, 2024 EMA Recommends Refusal of the Marketing Authorisation for Pexidartinib July 3, 2020 The First Report from the Cancer Programme of the 100,000 Genomes... January 16, 2024 Incidence of Colorectal, Breast, Kidney, Pancreatic, and Uterine Cancers is Increasing... May 18, 2022 Load more HOT NEWS Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September Answers to Your Questions About Sunscreen Ingredients Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed... Molecular Determinantion of Outcomes in a Study with Pembrolizumab for Advanced...
